Mifobate

SKU: orb1308042

Description

Mifobate (SR-202) is a potent and selective PPARγ antagonist. This small molecule research compound has demonstrated anti-obesity, anti-diabetic, and anti-atherosclerotic properties in scientific studies, making it a useful tool for investigating metabolic and cardiovascular diseases in both in vitro and in vivo models.

Research Area

Metabolism Research, Molecular Biology

Key Properties

• CAS Number: 76541-72-5
• MW: 358.65
• Purity: 100.00% (May vary between batches)
• Formula: C₁₁H₁₇ClO₇P₂
• SMILES: C(P(OC)(OC)=O)(OP(OC)(OC)=O)C1=CC=C(Cl)C=C1
• Target: PPAR
• Solubility: H2O:35.87 mg/mL (100.01 mM)

Bioactivity

• Target IC50:
  PPARγ:140 μM (IC50)
• In Vivo:
  In vivo, decreasing PPARgamma activity, either by treatment with SR-202 or by invalidation of one allele of the PPARgamma gene, leads to a reduction of both high fat diet-induced adipocyte hypertrophy and insulin resistance. These effects are accompanied by a smaller size of the adipocytes and a reduction of TNFalpha and leptin secretion. Treatment with SR-202 also dramatically improves insulin sensitivity in the diabetic ob/ob mice.
  Read more...
• In Vitro:
  SR-202 is a new synthetic PPARgamma antagonist,, which inhibits both TZD-stimulated recruitment of the coactivator steroid receptor coactivator-1 and TZD-induced transcriptional activity of the receptor. In cell culture, SR-202 efficiently antagonizes hormone- and TZD-induced adipocyte differentiation.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, obesity, Mifobate, Inhibitor, differentiation, diabetes, antidiabetic, antiobesity, adipocyte, activity, transcriptional, type 2, selective, PPARγ, PPAR, Peroxisome proliferator-activated receptors, stimulation, SR202, SR-202, SR 202

Compound Identifiers

PubChem CID

60910